Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome.

Journal of neurology·2023
Same author

Electrophysiological Changes After Human Muscle Tear: A Potential Confounder.

American journal of physical medicine & rehabilitation·2019
Same author

Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients.

Journal of clinical apheresis·2015
Same author

Amyotrophic lateral sclerosis in a patient with a family history of huntington disease: genetic counseling challenges.

Journal of genetic counseling·2014
Same author

Multifocal motor neuropathy.

Seminars in neurology·2013
Same author

Late-onset Pompe's disease.

Seminars in neurology·2013
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

Inflammatory and toxic myopathy.

James W Teener1

  • 1Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan 48109-5036, USA. jteener@med.umich.edu

Seminars in Neurology
|May 17, 2013
PubMed
Summary
This summary is machine-generated.

Early recognition of treatable muscle diseases, like inflammatory myopathies, is key to restoring patient strength. Promptly identifying and removing muscle toxins also significantly improves outcomes.

Related Experiment Videos

Last Updated: May 11, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

Area of Science:

  • Neurology
  • Rheumatology
  • Clinical Medicine

Background:

  • Muscle diseases, while uncommon, necessitate prompt clinical recognition for effective treatment.
  • Several myopathies are treatable, offering opportunities to restore muscle strength.
  • Distinguishing between different myopathies is crucial for appropriate management.

Purpose of the Study:

  • To highlight the importance of recognizing treatable myopathies.
  • To discuss the role of immunosuppressive therapy in inflammatory myopathies.
  • To emphasize the impact of toxins on muscle function and the necessity of their removal.

Main Methods:

  • Review of clinical presentations and treatment responses for various myopathies.
  • Categorization of myopathies into inflammatory, degenerative, and toxin-induced.
  • Identification of common muscle toxins and their effects.

Main Results:

  • Inflammatory myopathies (polymyositis, dermatomyositis, etc.) generally respond well to immunosuppression.
  • Inclusion body myositis presents challenges, with ongoing research for treatments.
  • Toxin-induced muscle dysfunction is often reversible upon removal of the causative agent.

Conclusions:

  • Timely diagnosis of myopathies is essential for successful treatment and strength restoration.
  • Immunosuppressive therapy is effective for inflammatory myopathies.
  • Awareness of muscle toxins and their prompt elimination is critical for muscle recovery.